Do you consider an ovarian cancer patient who progresses on PARP inhibitor, either for treatment or maintenance, to be platinum resistant regardless of time since last platinum based chemotherapy?

I would not necessarily. The time since the last platinum is what would drive my answer. It may pan out in fact that the patient is no longer platinum sensitive, but I would not make that determination based on an assumption that progression on PARP = platinum resistance. Although we do say that pla...